IGF-1 LR3
Long-Arginine-3 IGF-1 Variant
IGF-1 LR3 is a long-acting variant of Insulin-like Growth Factor 1, engineered with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF-binding proteins by up to 100x compared to native IGF-1 — extending its active half-life from ~12 minutes to approximately 20 hours.
At a Glance
Native IGF-1 is rapidly sequestered by binding proteins (IGFBPs) that limit its bioavailability and activity window. LR3 modification circumvents this sequestration — the same total IGF-1 activity is distributed over a 20-hour window rather than minutes, fundamentally changing its research utility.
IGF-1 operates downstream of the GH axis — GH stimulates hepatic IGF-1 production, which then drives tissue growth, protein synthesis, and cellular metabolism. LR3 provides direct, sustained access to IGF-1 signaling without going through the GH pathway.
Muscle satellite cell activation, protein synthesis enhancement, and cellular hyperplasia (new cell formation) are among its most studied effects — making it one of the most anabolically-focused research peptides available.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
IGF-1 Receptor Agonism
Binds IGF-1R with the same affinity as native IGF-1, activating downstream PI3K/Akt and MAPK/ERK pathways governing cell growth, survival, and metabolism.
Extended Half-Life (~20h)
IGFBP resistance extends active half-life from ~12 minutes to ~20 hours — providing sustained receptor engagement from a single daily injection.
Satellite Cell Activation
Activates muscle satellite cells (myosatellite cells) — the stem cells responsible for muscle fiber repair and growth — a key mechanism in muscle mass research.
Protein Synthesis & Hyperplasia
Drives muscle protein synthesis and promotes cellular hyperplasia (new cell formation) rather than simply hypertrophy — a mechanistically distinct anabolic pathway.
Preclinical and clinical models have investigated this compound across a wide range of physiological contexts and tissue types.
- Muscle growth and satellite cell activation research — primary studied application
- Protein synthesis studies — PI3K/Akt pathway activation and downstream anabolic signaling
- Hyperplasia vs hypertrophy models — distinguishing cell multiplication from cell enlargement
- Recovery from muscle wasting (cachexia, sarcopenia) — anabolic support research
- Comparison with native IGF-1 — IGFBP resistance and extended activity characterization
- GH axis bypass models — direct IGF-1 signaling without upstream GH stimulation
- Wound healing and tissue repair — IGF-1 receptor contributions to cellular regeneration
IGF-1 LR3's combination of extended half-life and IGFBP independence makes it the most practical IGF-1 variant for research designs requiring sustained IGF-1 receptor engagement.
IGF-1 LR3, native IGF-1, and MK-677 offer three different approaches to studying IGF-1 pathway signaling — direct sustained, direct brief, and indirect via GH.
| Aspect | IGF-1 LR3 | Native IGF-1 | MK-677 |
|---|---|---|---|
| Half-Life | ~20 hours | ~12 minutes | ~24 hours |
| IGFBP Binding | Minimal (resistant) | Extensive (sequestered) | Indirect (via GH) |
| Source of IGF-1 | Direct — bypasses GH axis | Direct | Indirect — hepatic production |
| Anabolic Potency | High — sustained receptor activation | Limited by sequestration | Moderate via GH elevation |
| Best Research Use | Direct IGF-1 signaling studies | Short-duration pulse studies | Oral GH axis stimulation |
The following reflects findings from published preclinical and clinical safety assessments where available.
Extended half-life — 20 hours vs 12 minutes for native IGF-1, fundamentally improving research utility
IGFBP resistance — circumvents the sequestration that limits native IGF-1 bioavailability
Direct IGF-1 pathway access — bypasses GH axis variability for cleaner downstream studies
Hypoglycemia risk — IGF-1 has insulin-like effects; blood glucose monitoring is important in research designs
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026